Form 4: NEOGENOMICS Officer Receives Equity Grants

Neogenomics' Chief Accounting Officer, Greg D. Aunan, was granted new stock options and restricted stock units as part of his compensation.

Summary

• Greg D. Aunan, Chief Accounting Officer of Neogenomics Inc. (NEO), received new equity grants.
• On March 1, 2026, Mr. Aunan was granted 36,825 stock options with an exercise price of $9.83, expiring on March 1, 2036. These options vest ratably over the first three anniversary dates of the grant.
• On March 1, 2026, Mr. Aunan was also granted 22,889 restricted stock units (RSUs). These RSUs vest ratably over the first three anniversary dates of the grant, and once vested, the shares are not subject to expiration.
• Following these transactions, Mr. Aunan directly beneficially owns 22,027 shares of common stock.
• The filing also details his beneficial ownership of previously granted derivative securities, including stock options and restricted stock units from May 2023, May 2024, and February 2025, with various vesting schedules and exercise prices.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices aimed at aligning management incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The grants align the Chief Accounting Officer's interests with shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining and motivating key executives.

Negatives

• Potential for dilution of existing shareholder value upon exercise of options or vesting of RSUs, though this is typical for equity compensation plans.

Risks

• No specific risks are mentioned in this Form 4 beyond the inherent risks of equity compensation, such as market price fluctuations affecting the value of the awards.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4, as it is a disclosure of past transactions.

Industry Context

StockSavvy.ai notes that equity grants to executive officers are a standard component of compensation packages across the biotechnology and diagnostic services industry. Such grants are designed to align executive incentives with long-term shareholder value creation, a common practice for companies like Neogenomics.

Comparison to Industry Standards

• Equity compensation for Chief Accounting Officers is a common practice in publicly traded companies, particularly in the healthcare and diagnostics sector.
• The vesting schedules (3-4 years) are typical for executive equity awards, comparable to practices at peers such as Guardant Health (GH) or Exact Sciences (EXAS), which also utilize multi-year vesting to encourage long-term retention and performance.
• The mix of stock options and restricted stock units is a balanced approach, offering both upside potential (options) and retention value (RSUs), consistent with best practices in executive compensation.

Related Party Transactions

• The grants of stock options and restricted stock units to the Chief Accounting Officer constitute a related party transaction, which is a standard, disclosed form of executive compensation.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting/exercise, but also benefits from incentivized management performance.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs.

Next Steps

• Vesting of the newly granted stock options and restricted stock units will occur ratably over the next three years from March 1, 2026.
• Vesting of previously granted awards will continue according to their respective schedules.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants to a key executive. While it aligns management incentives with shareholder interests, it does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

Neogenomics, NEO, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Executive Compensation, Greg D. Aunan, Chief Accounting Officer